RAPIGLINIDE VOG 1.0 combines two potent antidiabetic agents, Repaglinide (1mg) and Voglibose (0.3mg), to effectively manage blood sugar levels in patients with type 2 diabetes. This combination therapy helps enhance insulin secretion and slow down carbohydrate absorption, offering a comprehensive approach to blood glucose control.

How Does It Work?

• Repaglinide: Stimulates the pancreas to release insulin in response to meals, helping to control postprandial blood sugar spikes.
• Voglibose: Inhibits enzymes responsible for breaking down carbohydrates into glucose, delaying glucose absorption and reducing post-meal blood sugar levels.

Uses of RAPIGLINIDE VOG 1.0

• Management of type 2 diabetes mellitus
• Reduction of postprandial hyperglycemia
• Prevention of diabetes-related complications

What is RAPIGLINIDE VOG 1.0?

RAPIGLINIDE VOG 1.0 is an oral antidiabetic medication that combines Repaglinide, a meglitinide analog, and Voglibose, an alpha-glucosidase inhibitor. This dual-action drug is designed to help patients achieve better glycemic control.

Side Effects

• Hypoglycemia (low blood sugar)
• Gastrointestinal discomfort (bloating, diarrhea)
• Dizziness
• Headache
• Skin reactions (rash, itching)

Safety Information

• Dosage: Follow the prescribed dosage. Do not alter the dose without consulting a healthcare provider.
• Precautions:
  • Monitor blood sugar levels regularly.
  • Avoid skipping meals to prevent hypoglycemia.
• Interactions: Inform your doctor about all medications and supplements you are taking to avoid potential interactions.
• Contraindications: Not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment.

If You Need More Information About  RAPIGLINIDE VOG 1.0  Click here